@LiamCristiano @dangermanisreal high dose topical testosterone barely causes shutdown DHT in lower doses most definit...
Social commentary suggests high‑dose topical testosterone produces minimal shutdown of DHT, while lower doses may increase endogenous HPG (hypothalamic–pituitary–gonadal) activity. This thread is physiologic observation, not a corporate or product disclosure.
Linked assets
This thesis references the biological marker DHT (dihydrotestosterone). No company tickers, ETFs, products, or investable securities are identified.
@LiamCristiano @dangermanisreal high dose topical testosterone barely causes shutdown DHT in lower doses most definit... @LiamCristiano @dangermanisreal high dose topical testosterone barely causes shutdown DHT in lower doses most definitely increases natural HPG activity
Source proof
Source proof: Supported source proof | 2 extracted claims | 1 directional asset | 1 supporting author | headline-like title review
Underlying sources are social-media posts and informal commentary describing dose-dependent effects of topical testosterone on FSH, LH, and DHT, plus anecdotal recommendations and unrelated health tips. None include firm names, drugs, pricing, regulatory events, or trading catalysts.
Anecdotal claim: a client reports improved nocturia/sleep continuity after taking 20mg vitamin K2 (MK-4) before bed for 4 days. No clinical data, no identifiable public-company catalyst, and unclear market relevance.
Content discusses human endocrinology (GH/LH/IGF-1, insulin, Leydig cell sensitivity, HPG axis) and makes no explicit market, company, sector, macro, or investable-asset claims. Not directly translatable into a tradable catalyst without additional context (e.g., drug/company linkage, clinical results, regulation, product demand).
A social-media joke/comment about progesterone and relationship behavior; no financial, economic, or market-relevant information.
Anecdotal social post claims higher-dose Vitamin K2 (MK-4) plus Vitamin E (mixed tocopherols) improved testosterone/LH dynamics, with commentary that high LH can indicate reduced Leydig-cell sensitivity and oxidative stress/circadian factors. This is not investable as a catalyst by itself, but it loosely reinforces an existing supplement/ingredients demand narrative (fat-soluble vitamins, antioxidant positioning).
Commentary about an unspecified substance reducing FSH and LH modestly, in a dose-dependent manner. No company, drug, catalyst, or tradable asset is identified.
Discussion about physiological effects of topical testosterone and DHT on HPG axis activity; no explicit market, company, product, or investable asset referenced.
The source only states that the user has heard “tons of strong reviews” about @JK99928789839, with no identifiable company/ticker, product, catalyst, timeframe, or tradable implication.
Non-financial social post about skincare/sun exposure increasing skin sensitivity; no market, company, or asset implications.
Supporting authors
Content derives from one author thread and related social posts; attribution is to the original handles quoted in the thesis. No institutional research or peer‑reviewed studies are provided in these sources.
Unlock full thesis monitoring
This material is physiological and conversational in nature and does not constitute an investable thesis. Use it only as background on hormone-response hypotheses; consult clinical literature for definitive mechanisms or therapeutic implications.